Recently, sensitive chemiluminescence techniques have been used to monitor markers in immunoassays, since chemiluminescent compounds are commonly detectable at picomolar levels (11). The measurable range is wider, and the time required to develop and measure luminescence activity in a chemiluminescencelinked immunoassay (CLIA) is much shorter than that required for an enzyme immunoassay. Pratt et al. (10) developed a testosterone CLIA with the luminol-ovalbumin-testosterone conjugate, and Simpson et al. (13) described the labeling of antibodies to rabbit immunoglobulin G (IgG) with a luminol molecule.
We have developed a simple and sensitive chemiluminescence-linked immunoassay (CLIA) for determining mumps virus antibodies. Luminol molecules were used as markers, and polystyrene balls were used as antigen carriers. The CLIA was compared with an enzyme-linked fluorescence assay and a hemagglutination inhibition test on a total of 40 serum specimens obtained from 29 donors with natural infection or vaccination. There was good correlation between the three methods, and the sensitivity of the CLIA was about 10 times higher than that of the hemagglutination inhibition test, although it was slightly inferior to that of the enzyme-linked fluorescence assay. Moreover, the time course of light emission from the labeled antibody was rapid, and therefore in the CLIA the quantitation of the marker takes only a short time.
For serological diagnosis of mumps, neutralization, hemagglutination inhibition (HI), and complement fixation tests have been used conventionally. However, neutralization tests are tedious and time-consuming, HI tests require pretreatment of test sera to remove nonspecific inhibitors and natural agglutinins, and complement fixation tests are more cumbersome to perform than HI tests. The radioimmunoassay described by Daugharty et al. (1) was more sensitive and simpler than these conventional tests, but the assay is hampered by the cost of reagents and equipment and the disadvantage of handling radioisotopes. Leinikki et al. (8) have reported a simple, inexpensive, and reliable enzyme immunoassay for mumps virus antibodies and compared the assay with neutralization, HI, and complement fixation tests. This technique has proven sensitive, specific, and simple to perform.
Recently, sensitive chemiluminescence techniques have been used to monitor markers in immunoassays, since chemiluminescent compounds are commonly detectable at picomolar levels (11) . The measurable range is wider, and the time required to develop and measure luminescence activity in a chemiluminescencelinked immunoassay (CLIA) is much shorter than that required for an enzyme immunoassay. Pratt et al. (10) developed a testosterone CLIA with the luminol-ovalbumin-testosterone conjugate, and Simpson et al. (13) Preparation of anti-human IgG-luminol conjugate. Rabbit anti-human IgG (heavy chain-specific) was purchased from Miles Laboratories, Inc., Kankakee, Ill. The antiserum was purified by Na2SO4 precipitation, and the globulin fractions obtained were reacted with a diazonium salt of luminol (13) . A 5-mg amount of luminol was diazotized in 1 ml of ice-cold 1.2 N HCI with 5 mg of NaNO2. Then, the pH was adjusted to 8.5 by adding 1.25 ml of ice-cold borate buffer (0.5 M, pH 8.5) and 0.75 ml of N NaOH. A 0.6-ml quantity of this solution was added to 0.6 ml of a solution containing 25 mg of the IgG fractions of antihuman IgG serum, and the mixture was incubated overnight at 4°C. After dialysis against 0.2 M borate buffer (pH 8.0), the solution was further purified by applying it to an immunoadsorbent column prepared by coupling cyanogen bromide-activated Sepharose 4B (Pharmacia, Uppsala, Sweden) with human IgG. The specific luminol-immunoglobulin conjugate eluted by glycine hydrochloride buffer (0.1 M, pH 2.3) was adjusted to neutral pH with NaHCO:j. The conjugate solution was further diluted with PBS containing 0.5% Tween 20 (PBS-Tw) to give a final volume of about 250 ml and was used for CLIA.
Preparation of anti-human IgG-enzyme conjugate. Anti-human IgG described above was labeled with f3-D-galactosidase (Boehringer Mannheim, Ltd., West Germany) by using meta-maleimidobenzoyl-Nhydroxysuccinimide (MBS) as a coupling reagent as described by Kitagawa and Aikawa (6) . Briefly, the IgG fractions of the antiserum obtained by a combination of Na2SO4 precipitation and diethylaminoethylcellulose column chromatography (9) were mixed with MBS in tetrahydrofuran, and then the MBS-acylated immunoglobulin were incubated with the enzyme. Next, the reaction mixture was directly chromatographed on a Sepharose 6B column with PBS containing 1 mM MgCl2, 0.1% bovine serum albumin and 0.1% NaN:i (buffer A) as an eluant. The fractions of eluate containing the peak of enzyme activity were diluted with PBS-Tw to give a final enzyme activity of about 5 ,uU/ml (25°C; lactose as a substrate) (14) and used for ELFA.
CLIA and ELFA procedures. To 5-ml disposable plastic tubes (Eiken Kizai Co., Tokyo, Japan) were added 0.5-ml volumes of serial twofold dilutions of test sera. AU dilutions, starting at 1:50, were made with PBS-Tw described above. One polystyrene ball with adsorbed mumps virus antigen was then added to each tube. Buffer blanks, where serum was omitted, were included in each test, and the chemiluminescence and fluorescence intensities of the buffer blanks were subtracted from those of samples. After incubation at 37°C for 60 min, the serum samples were aspirated, and the balls were washed twice with 7 ml of distilled water. A 0.5-ml volume of labeled anti-human IgG in PBS-Tw was added to each tube. After incubation at 37°C for 180 min, the excess of the labeled antibody was washed away as described above. The balls were then assayed for either luminescence or f3-D-galactosidase activity.
In the CLIA, the balls were placed in disposable scintillation vials (Aloka Co., Tokyo, Japan), and 2 ml of 0.1 N NaOH was added. The tubes were placed in the reaction chamber of a liquid scintillation counter (LSC-671 type; Aloka Co., Tokyo, Japan), and the reaction was initiated by consecutive additions of 100 ,l of 5.4 mM H202 and 1 ml of 1.0 mM NaOCl in 0.1 N NaOH solution. Counts were accumulated for a period of 60s.
In the ELFA, the balls were placed in clean plastic tubes and to the tubes was added 0.5 ml of buffer A containing 10 ,ug of 4-methylumbelliferyl-,f-D-galactoside (P-L Biochemicals Inc., Milwaukee, Wis.) as a substrate. After overnight incubation at room temperature, the reaction was terminated by adding 3 ml of 0.1 M carbonate buffer (pH 10.5), and the fluorescence intensity of the solution was measured with a fluorometer with excitation at 365 nm and emission at 450 nm (3) .
HI tests. The Sever microtiter method was employed with M/15 PBS (pH 7.3) containing 0.0025% gelatin and 0.2% bovine serum albumin as diluent and with 0.3% adult chicken erythrocyte suspensions (12) . The same antigen preparation as used for CLIA and ELFA was used at 4 HA units as a hemagglutinin. To remove nonspecific inhibitors, 0.1 ml of a test serum was mixed with 0.3 ml of a 25% kaolin suspension. After being shaken at room temperature for 30 min, the mixture was centrifuged at 2,000 rpm for 20 min, and to the supernatant was added 0.05 ml of a 10% erythrocyte suspension for removing natural agglutinins. After being allowed to stand at 4°C for 60 min, the treated serum was centrifuged and the supernatant fluid was assayed for mumps HI activity.
RESULTS
Comparison of CLIA with ELFA and HI tests. Forty serum specimens from 29 donors with natural infection or vaccination were assayed by the three immunoassays, and their antibody levels were compared ( Fig. 1 and 2) . In CLIA and ELFA tests, these sera were serially diluted in twofold steps with PBS-Tw and as- revaccination sera (-), 24postvaccination the case for radeosmmunoassayst nd 7 sera with natural mumps infection
The CLIA presented here, however, has a few tssayed by both tests. Antibody levels are shortcomings. The main disadvantage is that the cs serum titers.
CLIA is inferior to the ELFA in reproducibility, as shown in Table 1 . This probably arose from the use of the liquid scintillation counter for the numps antibody levels. The results of measurement of chemiluminescence. This ELFA were expressed as serum titers. counter could not monitor light production inpoint used for positive specimens was cluding the peak because the peak light intensity ird deviations above the mean of nine was attained within a few seconds. Thus, the n sera with no detectable HI anti-counts per minute in this study represent total fore calculating the endpoint titers, measurements of light emission decaying from of buffer blanks was subtracted from the peak value. Recently, an apparatus designed of test sera and the negative control especially for luminescence measurement has ;ing the cutoff point, the endpoint titer become commercially available, and the use of read from the dilution factor as the such an apparatus, where the reagents are mixed of the nearest twofold serum dilution. in front of the photomultiplier, will make the of 24 postvaccination sera showed rapid monitoring of light emission possible, re-JIA titers ranging from 50 to 3, 200 . In suiting in an improvement of reproducibility and three positive sera with HI titers of sensitivity. However, triplicate or quadruplicate i 512 gave a higher titer of 3,200 (Fig. determinations of chemiluminescence may be LIA titers of these 24 sera correlated needed, because the timing of the addition of the ELFA and HI titers. Also, when reagents is a very important factor for light from natural mumps virus infection production even with the use of such a special were assayed by the three techniques, there was good correlation between the CLIA, ELFA, and HI tests. The sensitivity of the CLIA was about 10 times higher than that of the HI test, although it was slightly inferior to that of the ELFA.
Coefficients of variation in CLIA and ELFA tests. To investigate the reproducibiity and precision of CLIA and ELFA, the coefficients of variation were measured at four different antibody levels. Ten determinations of each 100-fold-diluted serum were carried out simultaneously in the intra-assay (Table 1) . Coefficients of variation in the CLIA were 6.1 to 30.5%, higher than those in the ELFA (3.3 to 13.7%). Especially at low antibody levels of HI titers 8 and 16, coefficients of variation exceeded 20%. (7) . Another shortcoming is a marked reduction in quantum yield involved in the diazotization of luminol molecules, possibly as a result of polymerization of diazoluminol. This loss of quantum yield might result in slightly lower serum titers in CLIA than in ELFA. Luminometry is essentially about three orders of magnitude more sensitive than fluorometry and has a wide range of linearity of measurement as a function of concentration of unknown, as is well known in adenosine triphosphate measurement. Therefore, reaction conditions should be reconsidered to improve the recovery of luminescence during coupling of luminol to antibody.
Luminometry requires neither radioactive reagents nor spectrographic equipment; light is simply generated and recorded by a phototube. It may become a widely used technique in the future, as pointed out by Glick (2) . In the CLIA developed for mumps virus antibodies, the development and measurement of luminescence activity are simple, and the stable luminol-antibody conjugate is readily prepared. The method has the advantage of radioimmunoassay in that neither radioactive nor chemiluminescent materials occur in most biological samples to be analyzed. Thus, the CLIA is likely to be useful in small laboratories where isotope-counting equipment is not readily available and in larger centers where rapid results are desired.
Further studies will be conducted to prepare luminol-antibody conjugates without a marked reduction in quantum yield and to apply this CLIA test to other virus-and class-specific antibody determinations.
